Core Insights - Acumen Pharmaceuticals is advancing research on a novel therapeutic targeting soluble amyloid beta oligomers (AβOs) for Alzheimer's disease, presenting findings at the 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference [1][2] - The company has demonstrated improved delivery of AβO-targeting monoclonal antibodies to the central nervous system using the transferrin receptor (TfR) pathway, which may enhance brain distribution and efficacy [1][3] - Recruitment strategies from the Phase 2 ALTITUDE-AD clinical trial indicate that site databases and physician referrals are the most effective methods for participant recruitment [1][4] Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for Alzheimer's disease, specifically targeting toxic soluble AβOs [9] - The investigational product candidate, sabirnetug (ACU193), is a humanized monoclonal antibody that selectively targets soluble AβOs and has received Fast Track designation from the FDA for early Alzheimer's disease treatment [6][9] - The ALTITUDE-AD trial, initiated in 2024, is a Phase 2 study evaluating the efficacy and safety of sabirnetug in slowing cognitive decline in early Alzheimer's disease patients [8] Research and Development - The collaboration with JCR Pharmaceuticals has led to the development of TfR-targeting antibodies for clinical testing, enhancing the delivery of AβO-targeting therapies [1][2] - Fusion of TfR-binding antibody fragments with ACU193 has resulted in significant increases in brain penetration, achieving 15 to 68 times higher levels in mouse models [3] - The ALTITUDE-AD trial has screened 2,362 participants across 76 sites, with 542 enrolled, providing insights for improving future trial recruitment efficiency [4][8]